F8 and autoimmune hemolytic anemia: Otherwise, BPAs are used combined with immunosuppression.5 Rarely, hFVIII can be used for patients with inhibitors >10 BU/mL combined with plasmapheresis or immunoadsorption.4,6 Newer approaches are biochemical rebalancing agents such as emicizumab, a monoclonal antibody that mimics the function of activated FVIII by enhancing the interaction between FIX/FIXa and FX/FXa.7 Immunosuppression is necessary to eradicate the autoantibodies in AHA alongside all treatments that stop bleeding, but relapses occur in 15–33% of cases after stopping treatment.8